Valsartan: a novel angiotensin Type 1 receptor antagonist

By Thürmann P.A.  

Expert Opinion on Pharmacotherapy, Vol. 1, Iss. 2, 2000-01 ,pp. : 337-350

Informa Healthcare

Access to resources Recommend Favorite

Cytostatic Properties of Some Angiotensin I Converting Enzyme Inhibitors and of Angiotensin II Type I Receptor Antagonists

By  

Current Pharmaceutical Design, Vol. 9, Iss. 9, 2003-04 ,pp. : 751-761

Bentham Science Publishers

Access to resources Recommend Favorite

Comparative effects of tamoxifen and angiotensin II type-1 receptor antagonist therapy on the hemodynamic profile of the ovariectomized female rat

By Pham-Dang My-Lan   Clement Robert   Mercier Isabelle   Calderone Angelino  

Canadian Journal of Physiology and Pharmacology, Vol. 81, Iss. 9, 2003-09 ,pp. : 915-919

NRC Research Press

Access to resources Recommend Favorite

Angiotensin-II Receptor Antagonist Alleviates Non-alcoholic Fatty Liver in KKAy Obese Mice with Type 2 Diabetes

By Yu F   Takahashi T   Moriya J   Kawaura K   Yamakawa J   Kusaka K   Itoh T   Sumino H   Morimoto S   Kanda T  

The Journal of International Medical Research, Vol. 34, Iss. 3, 2006-05 ,pp. : 297-302

Field House Publishing

Access to resources Recommend Favorite

Which Strategy Is More Effective for the Treatment of Cardiovascular Disease: High-Dose Angiotensin II Type 1 Receptor Antagonist Monotherapy or Combination Therapy?

By Miura Shin-ichiro   Saku Keijiro  

American Journal of Cardiovascular Drugs, Vol. 8, Iss. 2, 2008-01 ,pp. : 88-90

Adis International

Access to resources Recommend Favorite